No Data
No Data
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Amgen's MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Top Gap Ups and Downs on Tuesday: LLY, ZM, BBY and More
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Amgen Options Spot-On: On November 26th, 133.57K Contracts Were Traded, With 212.37K Open Interest
No Data
No Data
AB84 :
Blaazin1 : His about to fix America! For whom?
章允量 :
103165865 : goog
Hero123 : mooo
View more comments...